ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Anti-citrullinated Protein Autoantibodies (ACPAs)"

  • Abstract Number: 1243 • ACR Convergence 2021

    Real World Validation of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis: Analysis from the RISE Registry

    Huifeng Yun1, Jeffrey Curtis2, Lang Chen3, cassie Clinton3, Hubert van Hoogstraten4, Stefano Fiore4, Markus Rehberg5 and Ernest Choy6, 1University of Alabama Birmingham, Birmingham, AL, 2Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 3University of Alabama at Birmingham, Birmingham, AL, 4Sanofi, Bridgewater, NJ, 5Sanofi, Franfurt, Germany, 6CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom

    Background/Purpose: Accurately identifying patients who may respond better to a specific drug or mechanism of action could improve rational selection of medications to optimize clinical…
  • Abstract Number: 0034 • ACR Convergence 2021

    Immune Complexes Contain Novel Acetylated Antigens in the Synovial Fluid of RA Patients

    Khetam Ghannam1, Holger Bang2, Thomas Häupl1, Eugen Feist3 and Gerd Burmester4, 1Charite University Medicine Berlin, Berlin, Germany, 2Orgentec Diagnostika GmbH, Mainz, Germany, Mainz, Germany, 3Helios Department of Rheumatology, Vogelsang-Gommern, Germany, 4Charité University Medicine Berlin, Berlin, Germany

    Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by genetic predisposition and associated immunological features including the production of autoantibodies against various epitopes. Several…
  • Abstract Number: 1648 • ACR Convergence 2021

    Increasing Rates of Positivity of Autoantibodies Indicates a Shorter Time-to-Diagnosis of Future Rheumatoid Arthritis

    Dylan Bergstedt1, Ryan Peterson2, Marie Feser1, LauraKay Moss1, Geoffrey Thiele3, Ted Mikuls3, Jess Edison4, V. Michael Holers1 and Kevin Deane5, 1University of Colorado Denver, Aurora, CO, 2Colorado School of Public Health, Aurora, CO, 3University of Nebraska Medical Center, Omaha, NE, 4Walter Reed National Military Medical Center, Bethesda, MD, 5University of Colorado Denver, Denver, CO

    Background/Purpose: Rheumatoid arthritis (RA) has a ‘pre-RA’ period that can be defined by elevations in autoantibodies to citrullinated protein antigens (ACPA) and rheumatoid factor (RF)…
  • Abstract Number: 0037 • ACR Convergence 2021

    Identification and Validation of Four Circulating Autoantibodies Associated with the ACPA Status in Early Rheumatoid Arthritis

    Lucía Lourido1, Cristina Ruiz-Romero2, Lidia Collado1, Monika Hansson3, Lars Klareskog4, Ronald Sjöberg5, Elisa Pin5, Peter Nilsson5 and Francisco Blanco-García6, 1Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, España., A Coruña, Spain, 2Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, España.Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN). Av. Monforte de Lemos, 3-5. Pabellón 11, 28029, Madrid, España., A Coruña, Spain, 3Division for Rheumatology, Karolinska Institutet, Stockholm, Sweden, 4Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, 5Division of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology & SciLifeLab, Stockholm, Sweden, 6Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, España.Universidade da Coruña (UDC), Grupo de Investigación de Reumatología y Salud (GIR-S). Departamento de Fisioterapia, Medicina y Ciencias Biomédicas, Facultad de Fisioterapia, Campus de Oza, 15008, A Coruña, España., A Coruña, Spain

    Background/Purpose: The presence of anti-citrullinated protein antibodies (ACPAs) is a highly specific hallmark of rheumatoid arthritis (RA), that is present also in early disease. However,…
  • Abstract Number: 1652 • ACR Convergence 2021

    Symptom Burden in Anti-citrullinated Protein Antibody Positive Individuals At-risk for Rheumatoid Arthritis Is Changing over Time and Comparable to Patients with Early Rheumatoid Arthritis

    Paul Studenic1, Alexandra Circiumaru2, Daniel Aletaha3, Katerina Chatzidionysiou4, Anca Catrina5 and Aase Haj Hensvold6, 1Karolinska Institute; & Medical University of Vienna, Stockholm, Sweden, 2Division for Rheumatology, Karolinska Institutet; Center for Rheumatology, Academic Specialist Center, Stockholm Region, Stockholm, Sweden, 3Medical University Vienna, Vienna, Austria, 4Karolinska Institute, Division of Rheumatology; & Karolinska University Hospital, Rheumatology Unit, Stockholm, Sweden, 5Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, 6Karolinska Institutet, Division for Rheumatology; & Center for Rheumatology, Academic Specialist Center, Stockholm Region, Stockholm, Sweden

    Background/Purpose: Symptom burden in individuals at risk for developing rheumatoid arthritis (RA) - positive for anti-citrullinated peptide antibodies (ACPA) and musculoskeletal complaints - has not…
  • Abstract Number: 0038 • ACR Convergence 2021

    Arthritis Progression in at Risk Individuals Is Associated with ACPAs Not AMPAs

    Alexandra Circiumaru1, Yogan Kisten2, Monika Hansson2, Heidi Wähämaa3, Meng Sun3, Vijay Joshua3, Hamed Rezaei4, Erik Af Klint4, Aleksandra Antovic1, Anca Catrina3 and Aase Haj Hensvold5, 1Division for Rheumatology, Karolinska Institutet; Center for Rheumatology, Academic Specialist Center, Stockholm Region, Stockholm, Sweden, 2Division for Rheumatology, Karolinska Institutet, Stockholm, Sweden, 3Karolinska Institutet and Karolinska university Hospital, Stockholm, Sweden, 4Division for Rheumatology, Karolinska Institutet; Department of Rheumatology, Karolinska University Hospital, Stockholm, Sweden, 5Karolinska Institutet, Division for Rheumatology; & Center for Rheumatology, Academic Specialist Center, Stockholm Region, Stockholm, Sweden

    Background/Purpose: Individuals with anti citrullinated protein antibodies (ACPA) and musculoskeletal complaints are at high risk for developing rheumatoid arthritis (RA) and often seek medical attention…
  • Abstract Number: 1654 • ACR Convergence 2021

    Comparative Characteristics of the Natural Course of Early Rheumatoid Arthritis with Onset at a Young Age (18-49 Years) and Older (50 Years and Older) Patients Who Did Not Take DMARDs, Biologics, Other Targeted Drugs, Corticoids According to the Russian Register of Arthritis OREL

    Azamat Satybaldyev, Galina Gridneva, Anna Misiyuk, Natalia Demidova, Kamalia Kasumova and Evgeny Nasonov, V.A. Nasonova Reseach Institute of Rheumatology, Moscow, Russia

    Background/Purpose: Comparison of frequency of different clinical features of the natural course at the stage of early rheumatoid arthritis (RA) in patients with young and…
  • Abstract Number: 0039 • ACR Convergence 2021

    Elevated IgA Subclass Levels in Rheumatoid Arthritis Patients: Indications of a Mucosal Origin?

    Veerle Derksen, Cornelia F. Allaart, Annette H.M van der Helm-van Mil, Tom WJ Huizinga, René Toes and Diane van der Woude, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Mucosal surfaces may be involved in the pathophysiology of rheumatoid arthritis (RA) (1). IgA is the most abundant class of immunoglobulin at mucosal sites…
  • Abstract Number: 0042 • ACR Convergence 2021

    High-throughput Testing for Modified-protein Antibodies in Patients Diagnosed with “Seronegative” Rheumatoid Arthritis

    Michael Richter1, Hari Krishnamurthy2, Sylvia Posso3, Jeffrey Carlin4 and Jane Buckner3, 1University of Washington, Mercer Island, WA, 2Vibrant Sciences, San Carlos, CA, 3Benaroya Research Institute at Virginia Mason, Seattle, WA, 4Virginia Mason Medical Center, Seattle, WA

    Background/Purpose: Antibodies to citrullinated and other modified proteins play a critical role in the pathogenesis of rheumatoid arthritis (RA). The prevalence and degree of multi-site…
  • Abstract Number: 0228 • ACR Convergence 2021

    Optimizing Social Media as a Recruitment Tool for Hard-to-Reach Populations in Rheumatology Clinical Research

    Vladislav Tsaltskan1, Katherine Nguyen1, Christina Eaglin1, Kevin Deane2, V. Michael Holers3 and Gary Firestein1, 1University of California San Diego, San Diego, CA, 2University of Colorado Denver, Denver, CO, 3University of Colorado, Denver, CO

    Background/Purpose: Standard methods of recruitment for clinical research, such as traditional media advertisements, can be inefficient and expensive, especially for underserved communities and asymptomatic individuals.…
  • Abstract Number: 0269 • ACR Convergence 2021

    Autoantibodies and the Risk of Incident Cardiovascular Disease in US Veterans with Rheumatoid Arthritis

    Tate Johnson1, Michael Duryee2, Carlos Hunter2, Punyasha Roul2, Yangyuna Yang2, Jeremy Sokolove3, William Robinson4, Joshua Baker5, Geoffrey Thiele2, Ted Mikuls2 and Bryant England2, 1University of Nebraska Medical Center, Elkhorn, NE, 2University of Nebraska Medical Center, Omaha, NE, 3Stanford University School of Medicine, Berwyn, PA, 4Stanford University, Stanford, CA, 5University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Autoantibodies are hypothesized as one of the RA specific factors contributing to a heightened risk of cardiovascular disease (CVD) in this population. However, prior…
  • Abstract Number: 0288 • ACR Convergence 2021

    Demographic, Lifestyle, and Clinical Risk Factors for Rheumatoid Arthritis-Associated Bronchiectasis: Role of RA-related Autoantibodies

    Gregory McDermott1, Ritu Gill2, Staci Gagne3, Suzanne Byrne3, Weixing Huang3, Lauren Prisco4, Alessandra Zaccardelli3, Lily Martin3, Nancy Shadick5, Paul Dellaripa3, Tracy Doyle6 and Jeffrey Sparks3, 1Brigham and Women's Hospital, Brookline, MA, 2Beth Israel Deaconess Medical Center, Boston, MA, 3Brigham and Women's Hospital, Boston, MA, 4Brigham and Women's Hospital, Pound Ridge, MA, 5Brigham & Women's Hospital, Boston, MA, 6Brigham and Women's Hospital, West Roxbury, MA

    Background/Purpose: Bronchiectasis is a known extra-articular manifestation of rheumatoid arthritis (RA) characterized by bronchial damage and excessive mucus production that predispose patients to risk of…
  • Abstract Number: 0291 • ACR Convergence 2021

    IgA Anti-Cyclic Citrullinated Peptide Antibodies in Bronchoalveolar Lavage Fluid from Patients with Idiopathic Pulmonary Fibrosis Are Associated with Reduced Mortality

    Scott Matson1, Candace Cephers2, Timothy Wilson3, Valerie Minarchick3, Kevin Brown4, Joshua Solomon4 and Kristen Demoruelle5, 1University of Kansas, Kansas City, MO, 2St Joseph Hospital, Internal Medicine, Denver, CO, 3University of Colorado, Denver, CO, 4National Jewish Health, Denver, CO, 5University of Colorado Anschutz Medical Campus, Aurora, CO

    Background/Purpose: Idiopathic pulmonary fibrosis (IPF) is a form of interstitial lung disease (ILD) that shares many clinical features with rheumatoid arthritis (RA) associated ILD. Our…
  • Abstract Number: 0440 • ACR Convergence 2021

    Association Between Rheumatic Autoantibody Positivity and Immune-related Adverse Events

    Kristen Mathias1, Marco Lopez Velazquez1 and Pankti Reid2, 1University of Chicago, Chicago, IL, 2University of Chicago Medical Center, Chicago, IL

    Background/Purpose: The advent of immune checkpoint inhibitors (ICIs) has revolutionized cancer therapy; however, their use can lead to off-target toxicities called immune-related adverse events (irAEs)…
  • Abstract Number: 0461 • ACR Convergence 2021

    Plasmablast-derived Autoantibodies from Individuals At-risk for RA That Target RA-relevant Antigens Are Polyreactive with Arthritogenic Bacteria

    Meagan Chriswell1, Jennifer Seifert2, Michelle Bloom3, Cliff Rims4, Marie Feser5, Kevin Deane6, Jill Norris7, Eddie James8, Jane Buckner9, William Robinson10, V. Michael Holers11 and Kristine Kuhn12, 1UC Denver SOM, Denver, CO, 2University of Colorado School of Medicine, Littleton, CO, 3Stanford University, Redwood City, CA, 4Benaroya Research Institute, Seattle, WA, 5University of Colorado Denver, Aurora, CO, 6University of Colorado Denver, Denver, CO, 7Colorado School of Public Health, Aurora, CO, 8Benaroya Research Institute at Virginia Mason, Monroe, WA, 9Benaroya Research Institute at Virginia Mason, Seattle, WA, 10Stanford University, Palo Alto, CA, 11University of Colorado, Denver, CO, 12University of Colorado Anschutz Medical Campus, Aurora, CO

    Background/Purpose: Circulating autoantibodies like ACPA frequently develop years before symptoms of RA, during which the individual is at-risk for disease. Several lines of evidence suggest…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology